

David R. Dodds, Ph.D.

David Dodds has over 30 years experience leading interdisciplinary process development groups combining biological and chemical technologies to create new industrial processes.

David established Dodds & Associates in 2002 to provide technical consulting and management to start-up companies, initially in pharma and more recently in industrial biotech and renewable chemicals. He provides technical diligence to the investment community, expert witness service for patent infringement cases, serves on the technical advisory boards of zuChem and Purevision technology, and was a member of the original industrial advisory boards of Codexis and Kent BioEnergy. He is also a member of the Renewable Chemicals team at Lee Enterprises Consulting.

Working at the interface between chemistry and biology, his experience spans academic, venture, legal, and industrial cultures, from creating corporate technical strategy, to plant operations facing decisions in process scale-up, to directing hands-at-the-bench scientists solving problems in basic science.

David is co-founder of SriyaDXI, an IT start-up that uses machine learning to determine user experience during digital transactions, and serves as CTO for Pronghorn Renewables (now Sriya Green Enterprises), a bio-based chemical start-up targeting products from C5 sugars using process technologies from the petrochemical industry. He is a principal at BioChemInsights, which is using electrochemistry to improve the carbon efficiency of renewable fuels and chemicals production.

David's last corporate position was Director of Fermentation and Biocatalysis Development at Bristol-Myers Squibb. Among other responsibilities, he reviewed all third-party technology for the production of paclitaxel that was presented to BMS, and managed the scale-up of the fermentation for epothilone, the natural product used to produce the anticancer drug IXEMPRA® (Ixabepilone).

Prior to his invitation to BMS, David established and led the Biotransformations Group within Chemical Development at the Schering-Plough Research Institute (now Merck). His group successfully introduced biocatalysis in over a dozen projects, including the anti-cholesterol drug Zetia® and the anti-fungal Posaconazole®.

His first industrial position was at Sepracor, where his work led to patents covering the enzymatic synthesis of pharmaceutical intermediates, and provided multi-million dollar royalties.

David pursued post-doctoral work in molecular biology with Marvin Caruthers at the University of Colorado (1984-1986), Boulder. He obtained his Ph.D. in synthetic organic chemistry under Bryan Jones at the University of Toronto in 1984.

